172.97
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Agilent Technologies Inc stock is traded at $172.97, with a volume of 2.90M.
It is down -1.47% in the last 24 hours and up +12.54% over the past month.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
See More
Previous Close:
$175.55
Open:
$175.04
24h Volume:
2.90M
Relative Volume:
1.40
Market Cap:
$48.77B
Revenue:
$7.23B
Net Income/Loss:
$1.41B
P/E Ratio:
34.74
EPS:
4.979
Net Cash Flow:
$1.09B
1W Performance:
+1.42%
1M Performance:
+12.54%
6M Performance:
+46.27%
1Y Performance:
+22.59%
Agilent Technologies Inc Stock (A) Company Profile
Name
Agilent Technologies Inc
Sector
Industry
Phone
(408) 345-8886
Address
5301 STEVENS CREEK BLVD, SANTA CLARA, CA
Compare A vs TMO, DHR, NTRA, IDXX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
A
Agilent Technologies Inc
|
172.97 | 48.77B | 7.23B | 1.41B | 1.09B | 4.979 |
|
TMO
Thermo Fisher Scientific Inc
|
690.00 | 255.13B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
229.04 | 161.01B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
NTRA
Natera Inc
|
393.44 | 56.71B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
IDXX
Idexx Laboratories Inc
|
560.36 | 44.15B | 4.45B | 1.10B | 1.06B | 13.59 |
Agilent Technologies Inc Stock (A) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-26 | Resumed | UBS | Neutral |
| Jul-09-26 | Resumed | Jefferies | Hold |
| Jun-26-26 | Resumed | Bernstein | Outperform |
| Jun-11-26 | Initiated | Piper Sandler | Neutral |
| May-28-26 | Upgrade | BofA Securities | Neutral → Buy |
| May-27-26 | Initiated | RBC Capital Mkts | Outperform |
| Jan-20-26 | Initiated | HSBC Securities | Buy |
| Jan-05-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-15-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-09-25 | Initiated | Goldman | Buy |
| Dec-02-25 | Initiated | Morgan Stanley | Overweight |
| Oct-08-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-08-25 | Upgrade | UBS | Neutral → Buy |
| Feb-10-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Apr-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-17-23 | Downgrade | UBS | Buy → Neutral |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| May-24-23 | Reiterated | Barclays | Equal Weight |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | Citigroup | Neutral |
| May-24-23 | Reiterated | Credit Suisse | Outperform |
| May-24-23 | Reiterated | Evercore ISI | Outperform |
| May-24-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| May-24-23 | Reiterated | Robert W. Baird | Outperform |
| May-24-23 | Reiterated | SVB Securities | Outperform |
| May-24-23 | Reiterated | Stifel | Hold |
| May-24-23 | Reiterated | TD Cowen | Outperform |
| May-24-23 | Reiterated | Wells Fargo | Overweight |
| May-11-23 | Initiated | Barclays | Equal Weight |
| Jan-10-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-20-22 | Initiated | UBS | Buy |
| Jul-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-22 | Reiterated | BofA Securities | Buy |
| Feb-23-22 | Reiterated | Citigroup | Buy |
| Feb-23-22 | Reiterated | Cowen | Outperform |
| Feb-23-22 | Reiterated | Evercore ISI | Outperform |
| Feb-23-22 | Reiterated | Stifel | Hold |
| Feb-23-22 | Reiterated | Wells Fargo | Overweight |
| Nov-23-21 | Reiterated | BofA Securities | Buy |
| Nov-23-21 | Reiterated | Cowen | Outperform |
| Nov-23-21 | Reiterated | Stifel | Hold |
| Mar-18-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-25-20 | Upgrade | UBS | Neutral → Buy |
| Nov-17-20 | Upgrade | Cleveland Research | Neutral → Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-30-20 | Initiated | Atlantic Equities | Neutral |
| Aug-19-20 | Reiterated | BofA Securities | Neutral |
| Aug-19-20 | Reiterated | Citigroup | Neutral |
| Aug-19-20 | Reiterated | Jefferies | Buy |
| Aug-19-20 | Reiterated | Robert W. Baird | Outperform |
| Aug-19-20 | Reiterated | SVB Leerink | Outperform |
| Aug-19-20 | Reiterated | Stifel | Hold |
| Aug-19-20 | Reiterated | Wells Fargo | Overweight |
| Feb-24-20 | Downgrade | Needham | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-26-19 | Reiterated | Needham | Buy |
| Nov-15-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | UBS | Buy → Neutral |
| Jul-16-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-15-19 | Downgrade | Barclays | Overweight → Equal Weight |
View All
Agilent Technologies Inc Stock (A) Latest News
Agilent Technologies (NYSE:A): Re‑Accelerating After a Two‑Year Soft Patch Thanks to the Backbone of Regulated Labs - Stocks Down Under
Philly-based AI medical analysis start-up to be acquired for up to $270 million - Inquirer.com
Agilent to buy Proscia for $240M - MedTech Dive
Why Agilent Is Spending up to $270 Million on an AI Pathology Specialist - Benzinga
Agilent to Acquire Proscia for Up to $270M to Build Scientific Intelligence Layer in Digital Pathology - HIT Consultant
Agilent to expand capabilities in China - China Daily
UBS Adjusts Agilent Technologies Price Target to $180 From $165 - Moomoo
Agilent to buy pathology software maker Proscia for $240 million - Reuters
Agilent Technologies to Acquire Proscia for Up to $270 Million to Expand AI-Powered Digital Pathology Business - citybiz
Agilent Technologies (A) Acquires Proscia to Expand Digital Path - GuruFocus
Agilent Technologies to Acquire Proscia in All-Cash Deal - marketscreener.com
Agilent Technologies to Acquire Proscia in All-Cash Deal - Yahoo Finance
Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence - Business Wire
Agilent Technologies Inc. Research & Ratings | AGIL - Barron's
TD Cowen Adjusts Price Target on Agilent Technologies to $196 From $180 - www.marketscreener.com
Agilent Technologies Inc. Advanced Charts | AGIL - Barron's
CWC | Agilent Technologies Announces European High-Speed Digital Seminar Tour - Cambridge Wireless
Agilent Technologies, Inc.: Dividend historical data and projections - marketscreener.com
Is Agilent Technologies (A) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Agilent Technologies Inc. stock outperforms competitors on strong trading day - MarketWatch
Should You Invest in the First Trust Water ETF (FIW)? - Zacks Investment Research
Barclays Adjusts Price Target on Agilent Technologies to $195 From $175, Keeps Overweight Rating - marketscreener.com
Agilent Expands Oligonucleotide Manufacturing Capabilities With New Boulder Lab - CHEManager
Agilent Technologies Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.
Global Oligonucleotide Synthesis Reagents Market Size, Share, and Forecast, 2026-2033 | Therapeutics Demand Fuels 11.9% CAGR and USD 1.75 Billion Opportunity - GlobeNewswire Inc.
Magnetic Beads MarketGlobal Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion - GlobeNewswire Inc.
Agilent Technologies To Go Ex-Dividend On October 6th, 2026 With 0.255 USD Dividend Per Share - Moomoo
A6533886 Bond Yield and Price — FINRA:A6533886 - TradingView
AIgnite Execution And Long Replacement Cycles Will Support This Fairly Valued Bullish Case - Simply Wall Street
A5886204 Bond Profile: Coupon and Redemption - TradingView
Agilent Technologies Inc (A) Shares Fall 3.3% -- GF Value Says S - GuruFocus
Agilent Technologies Inc. Introduces The NovoStation Sample Preparation System For Automated Flow Cytometry Workflows - marketscreener.com
$1000 Invested In Agilent Technologies 15 Years Ago Would Be Worth This Much Today - Benzinga
Why Is Medtronic (MDT) Down 6.4% Since Last Earnings Report? - Zacks Investment Research
Agilent Technologies (A) Launches NovoStation Automation System to Enhance Flow Cytometry Workflow - GuruFocus
Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows - Yahoo Finance
Agilent Technologies Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Agilent Technologies Inc. Introduces Agilent Biotek Gen5 Ai Cell Identification Module - marketscreener.com
Bullish on Agilent Technologies Inc - The Globe and Mail
Agilent Ekes on Launch of BioTek - tradingview.com
Agilent launches AI cell identification software module - Investing.com
Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers - Yahoo Finance
A4881169 Bond Profile: Coupon and Redemption - tradingview.com
Agilent Technologies Inc. stock outperforms competitors on strong trading day - MarketWatch
Agilent Technologies Inc (A): GF Score of 96 Signals Strong Outp - GuruFocus
BofA Securities Maintains Agilent Technologies(A.US) With Buy Rating, Maintains Target Price $180 - Moomoo
Agilent Technologies (A) Tests Valuation On Exchange Offer And Recurring Revenue Story - Yahoo Finance
Agilent Technologies Inc (A) Shares Surge 4.5% -- What GF Score of 93 Tells Investors - GuruFocus
Why Agilent Technologies (A) Stock Is Up Today - Moomoo
Agilent Technologies Inc Stock (A) Financials Data
Revenue
Net Income
Cash Flow
EPS
Agilent Technologies Inc Stock (A) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dolsten Mikael | Director |
Sep 04 '26 |
Proposed Sale |
151.38 |
634 |
95,972 |
0 |
| Dolsten Mikael | Director |
May 29 '26 |
Proposed Sale |
135.42 |
1,600 |
216,672 |
0 |
| Dolsten Mikael | Director |
May 29 '26 |
Sale |
135.42 |
1,600 |
216,672 |
5,548 |
| Dolsten Mikael | Director |
Dec 01 '25 |
Proposed Sale |
149.81 |
2,600 |
389,510 |
0 |
| Dolsten Mikael | Director |
Dec 01 '25 |
Sale |
149.81 |
2,600 |
389,511 |
4,973 |
| Gonsalves Rodney | Officer |
Nov 26 '25 |
Proposed Sale |
154.99 |
3,000 |
464,956 |
0 |
| Gonsalves Rodney | V.P., Corporate Controller |
Nov 26 '25 |
Sale |
154.99 |
3,000 |
464,956 |
31,846 |
| MCDONNELL PADRAIG | President and CEO |
Nov 18 '25 |
Sale |
143.24 |
911 |
130,492 |
32,058 |
| MCDONNELL PADRAIG | Officer |
Nov 18 '25 |
Proposed Sale |
143.24 |
911 |
130,492 |
0 |
| MCDONNELL PADRAIG | President and CEO |
Nov 12 '25 |
Option Exercise |
109.86 |
12,490 |
1,372,151 |
45,938 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):